Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
Shareholders stand to receive a significant and attractive cash premium, as the purchase price of US1.19 per share, represents a compelling premium of 216% to the closing price on the Nasdaq on April 10, 2025, the date prior to the announcement of Future Pak’s initial non-binding proposal.Board unanimously recommends shareholders vote “FOR” the Arrangement.Shareholders are encouraged to review the circular carefully ...